X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ASTRAZENECA PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ASTRAZENECA PHARMA DIVIS LABORATORIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 18.5 94.8 19.5% View Chart
P/BV x 4.0 13.5 29.6% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 DIVIS LABORATORIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
ASTRAZENECA PHARMA
Mar-14
DIVIS LABORATORIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,4841,285 193.3%   
Low Rs918634 144.8%   
Sales per share (Unadj.) Rs142.3189.6 75.0%  
Earnings per share (Unadj.) Rs41.9-0.2 -20,570.9%  
Cash flow per share (Unadj.) Rs46.33.8 1,205.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs161.568.6 235.3%  
Shares outstanding (eoy) m265.4725.00 1,061.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.05.1 236.3%   
Avg P/E ratio x40.6-4,712.7 -0.9%  
P/CF ratio (eoy) x36.7249.6 14.7%  
Price / Book Value ratio x10.514.0 75.3%  
Dividend payout %23.90-   
Avg Mkt Cap Rs m451,52523,988 1,882.3%   
No. of employees `0003.71.6 237.8%   
Total wages/salary Rs m3,6491,605 227.4%   
Avg. sales/employee Rs Th10,184.43,040.2 335.0%   
Avg. wages/employee Rs Th984.11,029.2 95.6%   
Avg. net profit/employee Rs Th2,998.5-3.3 -91,840.6%   
INCOME DATA
Net Sales Rs m37,7644,740 796.7%  
Other income Rs m84892 921.2%   
Total revenues Rs m38,6124,832 799.1%   
Gross profit Rs m14,138-130 -10,891.8%  
Depreciation Rs m1,182101 1,167.8%   
Interest Rs m230-   
Profit before tax Rs m13,781-139 -9,921.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m2,6625 52,306.5%   
Profit after tax Rs m11,119-5 -218,438.1%  
Gross profit margin %37.4-2.7 -1,367.0%  
Effective tax rate %19.3-3.7 -527.2%   
Net profit margin %29.4-0.1 -27,416.2%  
BALANCE SHEET DATA
Current assets Rs m30,9472,726 1,135.1%   
Current liabilities Rs m5,1952,435 213.3%   
Net working cap to sales %68.26.1 1,109.2%  
Current ratio x6.01.1 532.0%  
Inventory Days Days11774 158.3%  
Debtors Days Days8541 208.9%  
Net fixed assets Rs m17,0271,035 1,644.6%   
Share capital Rs m53150 1,061.8%   
"Free" reserves Rs m42,341942 4,492.9%   
Net worth Rs m42,8771,716 2,498.7%   
Long term debt Rs m50-   
Total assets Rs m49,6844,156 1,195.5%  
Interest coverage x595.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.81.1 66.6%   
Return on assets %22.4-0.1 -18,310.0%  
Return on equity %25.9-0.3 -8,742.2%  
Return on capital %32.20-  
Exports to sales %85.35.7 1,495.6%   
Imports to sales %22.96.5 354.6%   
Exports (fob) Rs m32,198270 11,916.4%   
Imports (cif) Rs m8,654306 2,825.4%   
Fx inflow Rs m32,270375 8,614.6%   
Fx outflow Rs m8,775470 1,866.3%   
Net fx Rs m23,496-96 -24,590.2%   
CASH FLOW
From Operations Rs m10,379-8 -128,140.7%  
From Investments Rs m-4,135-146 2,837.8%  
From Financial Activity Rs m-6,241862 -723.9%  
Net Cashflow Rs m3709 0.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 0.3 3,933.3%  
FIIs % 19.0 15.7 121.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 9.1 189.0%  
Shareholders   31,796 12,856 247.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 09:09 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS